Argiris Symeonidis, MD, PhD, University of Patras, Patras, Greece, discusses the prognostic scoring system and independent variables used to assess the severity of a patient’s myelodysplastic syndrome (MDS). He also highlights some of the specific comorbid conditions such as cardiovascular disease, which cause non-leukemic death. This interview took place at the 2nd Regional Symposium on Myelodysplastic Syndromes (MDS 2020), held in Tel Aviv, Israel.